Investigational Drug Information for NYX-783
✉ Email this page to a colleague
What is the drug development status for NYX-783?
NYX-783 is an investigational drug.
There have been 3 clinical trials for NYX-783.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 13th 2021.
The most common disease conditions in clinical trials are Opioid-Related Disorders, Stress Disorders, Traumatic, and Stress Disorders, Post-Traumatic. The leading clinical trial sponsors are Aptinyx, Massachusetts General Hospital, and Premier Research Group plc.
Summary for NYX-783
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 11 |
| WIPO Patent Applications | 3 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2021-12-13) |
| Vendors | 0 |
Recent Clinical Trials for NYX-783
| Title | Sponsor | Phase |
|---|---|---|
| Safety, Tolerability and Pharmacokinetics of NYX-783 and Oxycodone DDI Study | National Institute on Drug Abuse (NIDA) | Phase 1 |
| Safety, Tolerability and Pharmacokinetics of NYX-783 and Oxycodone DDI Study | Yale University | Phase 1 |
| Safety and Efficacy of 50 mg NYX-783 QD vs. Placebo in PTSD | Worldwide Clinical Trials | Phase 2/Phase 3 |
Clinical Trial Summary for NYX-783
Top disease conditions for NYX-783
Top clinical trial sponsors for NYX-783
US Patents for NYX-783
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
